Sanofi-Aventis SA agreed to buy Genzyme Corp., ending a nine-month pursuit of the U.S. biotechnology company with a sweetened offer of at least $20.1 billion that gives France's biggest drugmaker treatments for rare diseases.
More...
Toggle signature
||||| Mentor Group Access Now! |||||
More...
Toggle signature
||||| Mentor Group Access Now! |||||